← FDA DRUG APPROVALS

FDA ANDA · ANDA216229

DEFERASIROX

Sponsor: ANNORA PHARMA

APPLICATION
ANDA216229
TYPE
ANDA
ORIGINAL APPROVAL
2022-09-22
LATEST ACTION
2024-03-19
ROUTE
ORAL
DOSAGE FORM
GRANULE
MARKETING STATUS
Prescription

Products

DEFERASIROXPrescription
DEFERASIROX 360MG · GRANULE · ORAL
DEFERASIROXPrescription
DEFERASIROX 90MG · GRANULE · ORAL
DEFERASIROXPrescription
DEFERASIROX 180MG · GRANULE · ORAL

Approval history

2024-03-19Labeling · Supplement 2 · standardAP
2023-03-16Manufacturing (CMC) · Supplement 1 · unknownAP
2022-09-22UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →